World-class health research at UCL awarded £145m

Pioneering health research and innovation, carried out at UCL's three Biomedical Research Centres (BRCs), will benefit from £145m new funding from the National Institute of Health Research (NIHR). UCL is the research partner of the NIHR UCLH BRC, awarded £90m, the NIHR Great Ormond Street Hospital (GOSH) BRC, awarded £35m, and the NIHR Moorfields BRC, awarded £20m. The total award to UCL is the most of any UK university and signals the strength of UCL's world-class translational research and scientific discovery. The funding, announced by the UK Government today, will be spread over five years from December 2022 to November 2027, and will directly benefit patients through the development of ground-breaking new treatments and new techniques to diagnose disease. Professor David Lomas, UCL Vice-Provost (Health), said: "I am delighted that the NIHR has recognised the outstanding work being done by our Biomedical Research Centres. "These collaborations between UCL Health and our NHS partners bring together academics and clinicians in a way that helps us translate breakthroughs in the lab into innovative new treatments, diagnostics and technologies. The renewed funding is excellent news and will result in real benefits for patients." In total 20 BRCs in England received awards totalling £790m, following an open and competitive process judged by international experts and members of the public.